SAB Biotherapeutics (SABS) Free Cash Flow (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Free Cash Flow data on file, last reported at -$14.5 million in Q1 2026.

• Quarterly Free Cash Flow fell 86.3% year-over-year to -$14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.5 million (down 63.26% YoY) and the FY2025 annual result came in at -$45.7 million, down 31.99% from the prior year.
• Free Cash Flow advanced to -$14.5 million in Q1 2026, from -$16.8 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.6 million in Q1 2023 to a low of -$16.8 million in Q4 2025.
• A 5-year average of -$8.5 million and a median of -$7.8 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 1504.71% — and 2023, when it soared 85.07%.
• Tracing SABS's Free Cash Flow over 5 years: stood at -$1.7 million in 2022, then slumped by 707.91% to -$13.5 million in 2023, then rose by 29.06% to -$9.6 million in 2024, then tumbled by 74.98% to -$16.8 million in 2025, then grew by 13.41% to -$14.5 million in 2026.
• The last three Free Cash Flow figures came in at -$14.5 million (Q1 2026), -$16.8 million (Q4 2025), and -$13.1 million (Q3 2025), per Business Quant data.